12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lantus insulin glargine: Phase IV data

The open-label, international Phase IV EASIE trial in 480 insulin-naïve early Type II diabetics inadequately controlled with metformin showed that once-daily Lantus as add-on to metformin significantly reduced HbA1c from baseline to 6 months, the primary endpoint, vs. once-daily 100 mg Januvia sitagliptin plus metformin (1.7%...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >